Stereotaxis appoints new chief executive officer


Stereotaxis announced that its board of directors has appointed Chairman William C Mills III to chief executive officer, effective February 12, 2014. Mills has been serving as interim chief executive officer since April 2013.

“Stereotaxis is now poised to build on our history of product innovation that can result in major advances in the delivery of patient cardiac therapies,” says Fred A Middleton, director. “We believe Bill is the right person to lead these initiatives during the next phase of our company’s development.”

“As chairman of Stereotaxis, I am very mindful of our potential as a leading innovator and provider of clinically validated robotic technology in the expanding global market for complex cardiac electrophysiology procedures, a market that is trending towards automation,” says William Mills, Stereotaxis board chairman and chief executive officer. “With the substantial recent progress we have made to strengthen the company’s financial position, we are increasingly focused on furthering our product innovation to improve patient outcomes, and I am very excited about the growth opportunities that we see ahead.”

According to a press release, Mills has served on the Stereotaxis board of directors since June 2000 and was elected chairman in May 2012. He has more than 30 years experience as a venture capitalist with an emphasis on science-based medicine and medical technology. Mills currently serves as a director on a number of venture capital, corporate and advisory boards, in addition to his role with Stereotaxis. He holds graduate degrees in chemistry and in management from Massachusetts Institute of Technology and an A B in Chemistry from Princeton University.